216
EVALUATION OF THE EFFECTIVENESS TREATMENT OF PULMONARY
HYPERTENSION IN CHILDREN WITH CONGENITAL HEART DEFECTS
Usmanov M., 403 group 1-pediatric faculty
Scientific director: Rahmatillaeva M. Sh.
the Department of Hospital Pediatrics
№
1 TPMI
Actuality
: Congenital heart defects (CHD) account for about 30% of all congenital malformations
in children. So, high pulmonary hypertension (PH) on the one hand, reducing the quality of life of operated
patients leads to early disability and premature death [1]. Still small and remains poorly studied dynamics
of the regression of PH and medication reduction in the period of pre-operative preparation of patients to
one or another correction of heart defects depending on weight and age. Therefore, revealing of laws of
development of high PH in different types of CHD in children, development of rational tactics of
medicament therapy, enhancing the quality of life and preparation for operational intervention when CHD
are relevant in the modern pediatric service.
Objective
:
Evaluate the clinical and functional efficiency of the use of phosphodiesterase type
5 inhibitor (sildenafil) and PAH, endothelin antagonist (bosentan) in the treatment of high pulmonary
hypertension in children with CHD.
Materials and methods
: To achieve the objectives for 2015-2018 at the Department of Hospital
Pediatrics
№
1, cardiologic and thoracic departments of the clinic of Tashkent pediatric medical Institute
conducted a survey of 78 children with CHD, hospitalized for inpatient treatment.
Results
: Treatment sildenafil in comprehensive pre-operative treatment in the main group revealed
reduction of pulmonary resistance and systolic blood pressure (SBA) in the right stomach on average 10-
14%. The use of combination therapy in the postoperative period in the main group helps to arrest severe
cardiovascular failure over a short period of time, reduction of residual pulmonary hypertension another 8-
10%.
Conclusions
: The combination therapy of the above drugs may be recommended in preoperative
period, as the efficiency of the therapy of heart insufficiency pulmonary hypertension, and also improves
the condition of patients.
References:
1.
Байахмедов
,
Ф
.
Ф
.,
Холметов
,
Ш
.
Ш
.,
Харисова
,
И
.
И
.,
Маль
,
Г
.
С
.,
Полякова
,
О
.
В
., &
Болдина
,
Н
.
В
. (2017).
ГИПОЛИПИДЕМИЧЕСКАЯ ТЕРАПИЯ БОЛЬНЫХ ИБС В УСЛОВИЯХ
ПОЛИМОРБИДНОЙ ПАТОЛОГИИ
.
В состав редакционной коллегии и организационного
комитета входят
, 399.
